Pfizer to remain aggressive on obesity market after setback

Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday. "Pfizer's position is that we believe that obesity is a place…

#pfizer #albertbourla #jpmorgan #elililly #mounjaro #novonordisk #glp1 #novoozempic #seagen #rsv